Auren Rx Review: $149 Either Molecule, No Lock-In

Almost every telehealth GLP-1 seller offers a discount for committing. Very few show you what you would pay if you did not. Auren Rx (aurenrx.com) publishes both numbers side by side on every product it sells — an auto-refill rate and an explicit single-month rate — and on the 1 September 2026 re-read it had done something rarer still: dropped both GLP-1s to the same figure. Semaglutide and tirzepatide now cost the same $149 a month, which takes the most common upsell in this category off the table entirely.

The two-rung ladder, and the price cut

Standard semaglutide is $149 a month on auto-refill, or $179 for a single month with no auto-refill. Standard tirzepatide is the same two figures. The microdose track runs $129 and $149 on the same basis.¹

Every one of those is lower than it was in August, when the same page read $199 and $169 for semaglutide and $299 and $259 for tirzepatide. That is a fall of $50 on semaglutide and $150 on tirzepatide at the no-commitment rung, and it is the reason the two molecules now sit at one price.

We file the auto-refill figure as the standing rate and print the single-month one beside it, because $30 is what keeping the right to walk away costs here and the site says so itself. There is no three-month rung, no six-month rung, no annual plan and no introductory month anywhere on the site. Nothing is being divided by anything, which removes the single most common source of fake monthly prices; the teaser-rate trap covers what that failure normally looks like.

Six months of either molecule is $1,074 on single months against $894 on auto-refill — $180 for the right to stop, or $30 a month.

Where the wrong price gets recorded

One trap survives the re-read and it is the one that matters for comparison shopping: the navigation and the cross-sell cards quote a floor from a different product line. The homepage prints NAD+ "from $125/mo" while the NAD+ page itself charges $179 on auto-refill and $209 for a single month. Nothing is fabricated; the heading is doing more work than the number can support.

In August we recorded two more, and they are worth knowing about even though we did not re-check them on 1 September: the weight-loss page loaded with tirzepatide already selected, so a glance filed the higher figure under semaglutide's name, and the site's own structured data published the subscribe rung rather than the no-commitment one. With both molecules now at $149 the first trap has nothing left to shift; the second would today put $149 where $179 belongs.

The microdose program is an actual program

Where most sellers mention microdosing as a line item, Auren Rx runs it as a named track with its own two-column price table across both molecules. At $129 on auto-refill and $149 for a single month it is one of the lower verified low-dose rungs we track anywhere — and the $20 gap between it and the standard track is small enough that the choice can be made clinically rather than financially.

The caveat is clinical, not commercial, and it does not shrink because a company has built a checkout around it: no randomized trial has tested below-label GLP-1 dosing for any outcome. What the evidence actually supports on GLP-1 microdosing is the piece to read before the price tempts you into it.

The rest of the shelf

NAD+ is the deepest line here and it is priced on the same two-column basis: $179 a month on auto-refill or $209 for a single month, across injection, nasal spray and cream.¹ Sermorelin, glutathione, GHK-Cu, tretinoin and minoxidil sit alongside it. There is no research-chemical shelf and no retatrutide.

Product pages carry star ratings with no review count and no source attached, and a review total that does not match the "hundreds of members" claim beside it. We do not repeat either.

The states, and what still is not settled

This has changed since August, though not cleanly. The site's own questions now say Auren Rx serves patients in all 50 states through affiliated providers and pharmacy partners. Its terms still say some services are "only available to individuals located in certain states", and no list is published to settle which sentence governs. An all-50 claim contradicted by the same company's terms is better than the August position of no claim at all, and it is still not an answer.

The pharmacy has changed in the right direction: VialsRX is now named, with a street address and a phone number, where August found only "one of our partner pharmacies". No 503A or 503B designation is stated for it.

The prescriber is where the disclosure now frays. The contact page and the questions name Wasef Health, PC and a physician behind it; the telehealth consent a patient signs names Beluga Health, P.A. instead. Two documents, two medical groups, and nothing on the site reconciles them. The corporate entity is Hades Capital LLC doing business as Auren RX, and it does publish a New York address.

One more thing to price before starting: the product pages and the refund policy advertise a free online visit, while the terms say the member is responsible for the cost of the initial online visit and any laboratory testing, and that neither is included in the membership fee. No figure is attached to either.

Billing and cancellation

The membership fee is charged the day membership commences, and it is non-refundable once paid. Membership begins after a provider communicates a care plan and you elect to proceed — so payment follows clinical review rather than preceding it, which is better than four of the other six programs we looked at this week.

Billing runs approximately every 28 to 30 days. That is disclosed, which is the whole difference between this and Vyvron's undisclosed four-week cycle — but at the short end of that range it is thirteen charges a year, about $1,937 rather than $1,788, and the marketing says "/mo" throughout. Cancellation is by email or in-account and stops all future charges; a pause is offered, with the caveat that eight or more consecutive weeks paused without a continuation review may end the membership outright.

The regulatory screen

The trading name, the legal entity, the medical group and the platform vendor all returned zero company-column matches in the FDA's live warning-letter index in August 2026.² The pass carried a positive control — a real February 2026 letter to an unrelated telehealth seller — which returned correctly, so the zeros mean what they appear to mean.

The verdict for a bargain hunter

On structure this is one of the cleanest price surfaces we have read: a single-month rung on everything, a disclosed billing cadence, one figure covering both molecules, and nothing to divide. On price the September cut moved it from mid-field to genuinely competitive — Trellis at $150 is now a dollar above it and Pepti at $109 every 28 days below. On disclosure it has improved and is still incomplete: a pharmacy is named, the states are claimed rather than listed and contradicted by its own terms, and two documents name two different medical groups. Budget thirteen charges a year at the short end of its own stated cycle. Weigh it against the field on the semaglutide price ladder and with how to choose a GLP-1 provider without overpaying, then check the rest of our research.